Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52
Behrens F, Leage SL, Sapin C, El Baou C, De La Torre I, Meszaros G, Schett G, Combe B, Van Den Bosch F, Gossec L (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1007/s10067-021-05891-5
Abstract
Introduction Improvements in both musculoskeletal and non-musculoskeletal manifestations are important treatment goals in psoriatic arthritis (PsA).
Authors with CRIS profile
Involved external institutions
Goethe-Universität Frankfurt am Main
Germany (DE)
Eli Lilly and Company
United States (USA) (US)
University of Montpellier / Université Montpellier
France (FR)
University Hospital Ghent
Belgium (BE)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Germany (DE)
Eli Lilly and Company
United States (USA) (US)
University of Montpellier / Université Montpellier
France (FR)
University Hospital Ghent
Belgium (BE)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
How to cite
APA:
Behrens, F., Leage, S.L., Sapin, C., El Baou, C., De La Torre, I., Meszaros, G.,... Gossec, L. (2021). Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52. Clinical Rheumatology. https://dx.doi.org/10.1007/s10067-021-05891-5
MLA:
Behrens, Frank, et al. "Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52." Clinical Rheumatology (2021).
BibTeX: Download